BioTissue Released Phase 2 Dry Eye Therapy Results
The Miami-based company reported safety and symptom improvements in a small trial for its TTAX03 therapy.
Updated on Oct. 10, 2026 in Biotech
Live Poll
Do you trust medical treatments developed from human birth tissue to be safe and effective?
BioTissue announced results from a Phase 2 trial of TTAX03, an experimental therapy for dry eye. The study evaluated 74 patients to assess safety and symptomatic change over a 12-week period.
Why it matters
As dry eye remains a common condition, researchers are seeking novel therapeutic interventions that move beyond existing treatments. This study establishes initial safety and efficacy signals, though broader research is still required to confirm the optimal dose and treatment regimen.
The study measured safety and ocular outcomes over 12 weeks, with high-dose groups demonstrating improved corneal staining resolution and changes in best-corrected visual acuity by Day 85 versus the control group.
The players
BioTissue
A Miami-based regenerative medicine company focused on ocular therapeutic technologies.
The details
The prospective, double-masked, multicenter study randomized 74 patients into four groups to receive one of three TTAX03 concentrations or saline. Participants received the treatment under a bandage contact lens—a soft lens used to protect the eye surface—for a duration of five days. Researchers monitored ocular and systemic safety throughout the 12-week study, noting no treatment-related serious adverse events.
Timeline
October 9, 2026: BioTissue announced the Phase 2 clinical results.
October 9-12, 2026: Results are presented at the American Academy of Ophthalmology annual meeting.
Day 85: Researchers measured changes in best-corrected visual acuity.
The Tech Race
BioTissue is positioning TTAX03 within a competitive field of experimental dry eye treatments presented at the American Academy of Ophthalmology Annual Meeting. The company aims to leverage its history of 420 peer-reviewed publications to advance this pipeline candidate toward future regulatory milestones.
The current results are from a research-stage trial, meaning TTAX03 is not yet available for clinical use. Patients and physicians should await further efficacy studies, which are necessary to determine final treatment protocols and long-term therapeutic outcomes.
The takeaway
While the Phase 2 data shows a positive safety profile and potential symptomatic benefit, the path to commercialization depends on future trials confirming efficacy. Interested parties should watch for the next round of study design announcements or updated peer-reviewed publications from the company.
Further reading
Learn more about the latest innovations in ocular science at the Biotech section.
More information
View the American Academy of Ophthalmology conference program for details on the study presentation.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust medical treatments developed from human birth tissue to be safe and effective?
